Squarepoint
BTAI icon

Squarepoint’s BioXcel Therapeutics BTAI Stock Holding History

Squarepoint’s Portfolio BTAI Stock Details BTAI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-4,503
Closed -$26.9K – 4621
2024
Q4 		$26.9K Buy
4,503
+3,021
+204% +$25.2K ﹤0.01% 4916
2024
Q3 		$14.5K Sell
1,482
-659
-31% -$8.86K ﹤0.01% 4039
2024
Q2 		$43.8K Buy
+2,141
New +$71.7K ﹤0.01% 3917
2024
Q1 		– Sell
-3,568
Closed -$168K – 4063
2023
Q4 		$168K Buy
+3,568
New +$198K ﹤0.01% 3658
2021
Q4 		– Sell
-590
Closed -$286K – 3176
2021
Q3 		$286K Sell
590
-1,369
-70% -$602K ﹤0.01% 2282
2021
Q2 		$911K Buy
+1,959
New +$1.07M ﹤0.01% 1696
2021
Q1 		– Sell
-648
Closed -$479K – 3142
2020
Q4 		$479K Buy
+648
New +$505K ﹤0.01% 1844
2020
Q2 		– Sell
-901
Closed -$322K – 2241
2020
Q1 		$322K Sell
901
-544
-38% -$196K 0.01% 1268
2019
Q4 		$338K Sell
1,445
-777
-35% -$78.1K ﹤0.01% 1978
2019
Q3 		$250K Buy
2,222
+212
+11% +$33.4K ﹤0.01% 1982
2019
Q2 		$352K Buy
+2,010
New +$340K ﹤0.01% 1852
2018
Q4 		– Sell
-1,156
Closed -$142K – 1951
2018
Q3 		$142K Buy
+1,156
New +$172K ﹤0.01% 1840

Other funds holding BTAI

M
Murchinson Toronto, Ontario, Canada $791M AUM 68.08% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BPA
Beacon Pointe Advisors Newport Beach, California $18.9B AUM 18.9% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
VF
Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return

Squarepoint's BTAI Position: Q1 2025 in Review

Squarepoint sold out of BioXcel Therapeutics (BTAI) in Q1 2025, closing a stake of 4,503 shares — an estimated $26.9K sold.

Squarepoint first reported a position in BTAI in Q3 2018 and held it in 12 quarters. The position peaked at $911K in Q2 2021. 31 funds tracked by Wall St. Rank hold BTAI as of Q1 2025.

  • Squarepoint reported no remaining BioXcel Therapeutics position as of Q1 2025 after selling out during the quarter.
  • Squarepoint sold 4,503 BioXcel Therapeutics shares in Q1 2025, an estimated $26.9K.
  • Squarepoint first reported a position in BioXcel Therapeutics in Q3 2018 and held it in 12 quarters.
  • Squarepoint's BioXcel Therapeutics position peaked at $911K in Q2 2021.
  • 31 funds tracked by Wall St. Rank held BioXcel Therapeutics as of Q1 2025.

Based on Squarepoint's 13F filing for Q1 2025, filed 15 May 2025.